Omnicare — Conference Presentation (November 2013)
32 slides from Omnicare's conference presentation, Nov 13, 2013
Slide 1: Omnicare
Omnicare
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain of the statements made today and listed within ji ion slides are f rd-looki ‘statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-| looking statements include, but: are not limited to, all statements regarding the int
Slide 3: Multi-Phased Operating Plan
Multi-Phased Operating Plan Operational Infrastructure Foundational to Strategic Execution a ” P Phase 1 | Phase 2 Phase 3 2Q12 3Q12 4Q12 1Q13 2013 3Q13 4Q13 + Development of transformational eee les strategy por for te. strategy for certain + Improved coordination ions and ‘account management suppo
Slide 4: Six Platforms, One Common Value Proposition
Six Platforms, One Common Value Proposition Centralized Approach Better Leverages Organizational Strengths Technology Innovators == "se Services Ser A Pharmacy Creating Value Clinical Operational Expertise Execution Three Pillars of Omnicare’s Value P ition provide for a point of differentiation tha
Slide 5: Multi-Phased Operating Plan: Improved Selling Effectiveness in Long-Term Care
Multi-Phased Operating Plan Results Reflect Improved Selling Effectiveness in Long-Term Care Quarterly Organic Sales — Long-Term Care Bed Additions 3Q12 4Q12 1013 2013 3Q13 Performance of sales organization reflects benefits of new strategy; 48% increase in new bed additions for 3Q YTD 32 omnicare 5
Slide 6: Multi-Phased Operating Plan: Long-Term Care Customer Experience Improving
Multi-Phased Operating Plan Long-Term Care Customer Experience Improving Long-Term Care ion Rate & C: Bed Losses“) 93.8% Annualized Retention Rate 4 Controllable Bed Losses 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 ™==Controllable Losses -®-Retention Rate Reduction in controllable losses an indication of e
Slide 7: Multi-Phased Operating Plan: Pathway to Sustainable Volume Growth
Multi-Phased Operating Plan Pathway to Achieving Sustainable Volume Growth Quarterly Net Organic Bed Growth Trend 1 H 1 696 (10,264) (23,759) 1Q12 2Q12 3Q12 4Q12 1013 2Q13 3Q13 Sales and retention initiatives have resulted in consecutive quarters of net bed growth following an average quarterly net
Slide 8: Multi-Phased Operating Plan: Robust Specialty Care Growth
Multi-Phased Operating Plan Emphasis on Continuing Robust Specialty Care Growth Quarterly SCG Revenues (in $ millions) 1012 2aie 3Q12 4a12 1013 2013 3013 in sales and keting areas have ensured continued strength in specialty pharmacy, fee-for-service platforms 2 omnicare 8
Slide 9: Omnicare Strategic Execution
RNY ly, “yg; Omnicare Strategic Execution
Slide 10: Residential to Skilled Nursing Pharmacy Approach
Residential — Independent Skilled Home Aide Living iving Ci Nursing Pharmac ‘ eg Choice Consumer Driven Institutionally Di Differentiated Approach Differentiated Traditional Institutional Pharmacy Services Omnicare (Build on ALF Refinement) Approach Strategy Current Status
Slide 11: Long-Term Care: Aging Population Shaping US Healthcare System
Long-Term Care Aging Population Shaping US Healthcare System‘) 425,000,000 400,000,000 3.0% CAGR 375,000,000 | s§ © 350,000,000 | 1.5% CAGR 3 2 5 2 925,000,000 3 300,000,000 0.4% CAGR 275,000,000 250,000,000 2 2016 2019-2022» 202520282031 «2034 = 2037 «2040-2043 Seniors’ utilization of pharmaceutica
Slide 12: Long-Term Care: Patient Migration Toward Cost-Effective Care Settings
Long-Term Care Patient Migration Toward Most Cost-Effective Care Settings Five-Year Cumulative % Change in ALF/SNF Markets and Occupancy Trend() 12% 90.0% n 10% $= = + 89.5% oN - 2 2% = —™s fa 89.0% fd a oe < 0% y = —,. — g 3 8% <—, 88.5% 5 8 a Se H 3 "Th 88.0% & g 8 2 ~ S 2% 7 pH < T * 875%? / 0% 8
Slide 13: Long-Term Care: Differentiated Platforms Provide Unique Growth Opportunities
Long-Term Care Differentiated Platforms Provide Unique Growth Opportunities Industry Developments Omnicare Growth Drivers Skilled Nursing Market in transition Focus on post-acute patients Increasing patient acuity, clinical complexity Market share gains Increased acuity levels Assisted Living Steady
Slide 14: Specialty Care Platforms and Omnicare Strategy
Brand Support | Patient Support Supply Chain Specialty ervices Services Solutions Pharmacy Fee-for-Service Buy/Sell Omnicare Fully Integrated, A La Cart Strategy Manufacturer-Focused, Patient-' comme Current Status
Slide 15: Specialty Care: Product Innovations Fueling Market Growth
Specialty Care Product Innovations Fueling Market Growth") FDA New Drug Approvals 64.0% 56.0% 48.0% 40.0% 32.0% 24.0% 16.0% 8.0% 0.0% 8.0% 2008 2009 2010 2011 2012 = Specialty Drugs = Tradtional NMEs © % Specialty Drugs Growth in specialty drug launches expected to continue with more than 900 specia
Slide 16: Specialty Care: Specialty Drug Cost Curve Increasing
Specialty Care Specialty Drug Cost Curve Increasing * Increase in specialty drug costs driven by product introductions, inflation % of Drug Costs by Product Type) 2012 | 2013 2014 2015 0% 20% 40% 60% 80% 100% Specialty Drugs ti Traditional Drugs Specialty Drug Spending > Expected three-year CAGR of
Slide 17: Specialty Care: Trends in Pharma Outsourcing
Specialty Care Trends in Pharma Outsourcing % Change in Pharma Outsourcing Expected During Next Year“) 100% 80% 28% _ 28% 25% fo 22% 40% 2% 49% 51% 51% 20% 44% 0% 2010 2011 2012 2013E sIncrease =No Change = Decrease Pharma outsourcing increasing due to industry consolidation and manufacturers’ incre
Slide 18: Manufacturer focused
Manufacturer focused Enhanced speed to therapy Flexible solutions adaptable to specific brand needs Efficient & timely capture of data, effective brand decisions Cost optimized Seamless, “One” patient experience
Slide 19: Accelerating Omnicare's Value Creation
Accelerating Omnicare’s Value Creation Focus on Operational Excellence, Strategic Execution Value Cr Capital Deployment | [ Strategic Execution Operational Infrastructure Enhancement Brand Support| Supply Chaln [Patient Support! Specialty | Skiled Nursing Assisted Ee Services Services Pharmacy acy R
Slide 20: Omnicare Financial Overview
RNY ly, “yg; Omnicare Financial Overview
Slide 21: Long-Term Care Group and Specialty Care Group
Long-Term Care Group came ; na Business Overview Customers Market Position Annual Prescriptions Specialty Care Group i
Slide 22: Omnicare's Primary Business: By the Numbers
Omnicare’s Primary Business By the Numbers LTM 9/30/13 Revenue) LTM 9/30/13 Adjusted Operating Income!)2\® mLong Term Care mSpecialty Care = Other Long Term Care Specialty Care = Other While LTC represents majority of operating income, SCG growth has recently outpaced LTC 1. SE a ait etary oat , GAA
Slide 23: Operating Performance
Operating Performance Five-Quarter Trend (in millions, except percentage data) 340 85% 320 84% 300 83% 28.0 82% 260 81% 240 80% 220 79% 200 78% sor 4Q12113_—NB 3B. saz aie 101s eats 03 ‘= LTC Presription Dispensed Generic Dispense Rate SiGDR excl. Short Cycle $1,700 $110 $1.00 $1,600 $105 $0.95 $1,5
Slide 24: Focus on Cash Flow
Focus on Cash Flow Cash Flow Drives Substantial Value Highly compelling financial attribute is cash flow generation capability — High quality of earnings — Creates flexibility for capital allocation initiatives Quarterly Adjusted EBITDA” vs. CFFO (in $ millions) 4qii 1012 2Q12 3Q12 4ai2 1013 2013 3Q
Slide 25: Capital Allocation Program: Capital Expenditures
Capital Allocation Program Capital Expenditures Maintenance capital expenditure requirements remain low — ~$40-$50 million Current capital expenditures elevated due to — OCEAN system investment — Technology and automation investments Hurdle rate for capital expenditure investment is approximately 15
Slide 26: Capital Allocation Program: Acquisitions
Capital Allocation Program Acquisitions + Disciplined approach to acquisitions — Minimum 15% after-tax returns — Strong operations without compliance issues - LTC — Strong growth trajectory to justify multiples - SCG + More disciplined approach has reduced the number and amount of acquisitions Histo
Slide 27: Focus on Returning Capital to Shareholders
Capital Allocation Program Focus on Returning Capital to Shareholders * Four-year track record of returning capital to shareholders — Increased dividend four times and over 500% since July 2010 ($0.56 /share/yr) — Approved four share repurchase authorizations totaling $850M total — 2013 YTD share bu
Slide 28: Capital Structure Initiatives
Capital Allocation Program Capital Structure Initiatives Major Debt Maturity Schedule 2) (in $ millions) $1,800 BAs of 9/30/10 BAs of 9/30/13 $1,500 $1,200 $300 | _| so | il 2010 2018 2020 2025 2030 2035 2045 Recent actions have reduced refinancing risk by spreading out maturities while also lowerin
Slide 29: Omnicare's Compelling Ability to Create Value
Slide 30: Omnicare
Omnicare
Slide 31: Omnicare Appendix
RNY ly, “yg; Omnicare Appendix
Slide 32: Exhibit - Segment Reconciliation
Exhibit 1 - Segment Reconciliation Last Twelve Months (“LTM”) September 30, 2013 Lcsaoe | crane | caters | oasis len ani 942012 912013 Q 93.2013 30,2013 ———kK——E—E_E—E—__E=SES ad Long Term Care Segment Revenue $ 1,233,547 $ 1,203,735 $ 1,222,352 $ 1,219,994 $ 4,879,628 Adjusted Operating Income: Ope